Warning signs: Acceleration in 483s, Warning Letters

The US FDA’s grip around drug manufacturers is getting tighter. While Form 483 observations were common earlier on, Indian players enjoyed a comfortable period of plant validations. In recent months, however, the FDA has pulled up several frontline Indian manufacturers, raising concerns on generic exports to the US. The US is one of India’s largest export destinations for generics and adverse reactions from the regulator carry the potential to dent medium‐term

revenues. With the US FDA strengthening its base in India, the pace of  483s and Warning Letters is unlikely to slow down. Considered a primary agency, actions by the FDA also often lay the path for crossborder regulatory alerts. On the bourses thus, these companies have felt the brunt of FDA setbacks. The FDA hiccups add a new dimension to the already challenging environment for generic companies.

In recent months many generic companies, including frontline Indian companies and their subsidiaries have been at the receiving end of the US FDA’s 483s and Warning Letters. While two companies – Caraco and Cipla ‐ have not proceeded beyond 483 observations, two – Ranbaxy and Lupin ‐ have snowballed to invoke Warning Letters. As the US FDA strengthens its base in India, the pace of 483s and Warning Letters is unlikely to slow down.